Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
Qi Cai, Gengwei Huo, Fuyi Zhu, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 7
Open Access | Times Cited: 15

Showing 15 citing articles:

Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 57
The Role and Mechanism of Metformin in Inflammatory Diseases
Huan Lin, Haiyong Ao, Guang‐hua Guo, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 5545-5564
Open Access | Times Cited: 24
Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
Jiayuan Le, Yuming Sun, Guangtong Deng, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 1
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
Qingyan Liu, Rong Li, Ling-ling LI, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease
María A. López-Olivo, Johncy John Kachira, Noha Abdel‐Wahab, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114148-114148
Closed Access | Times Cited: 5
Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma
Helene Broch Tenstad, Christina H. Ruhlmann, Søren Møller, et al.
Journal of Autoimmunity (2025) Vol. 152, pp. 103400-103400
Open Access
Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
Xin Liu, Li Su, Liyuan Ke, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors
Maria V. Deligiorgi, Dimitrios T. Trafalis
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7630-7630
Open Access | Times Cited: 4
Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis
Marco Bergamini, Alberto Dalla Volta, Francesca Valcamonico, et al.
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 56-68
Open Access | Times Cited: 1
Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung
Shunsuke Mori, Kazuyoshi Nakamura, Mitsuyo Shimamura, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6257-6257
Open Access | Times Cited: 1
Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes
R. Guitton, Olivier Lambotte, Laurent Chiche
La Revue de Médecine Interne (2023)
Closed Access | Times Cited: 2
Hepatobiliary complications of immune checkpoint inhibitors in cancer
Donna Zhuang, David Zhang, Stephen M. Riordan
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 4, pp. 955-970
Open Access
Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review
Stephanie Wuyts, Charlotte A.H. Cappelle, Marthe Verhaert, et al.
Journal of Oncology Pharmacy Practice (2023) Vol. 30, Iss. 1, pp. 55-66
Closed Access | Times Cited: 1
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top